InterveXion Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021...
top of page
InterveXion Therapeutics, LLC
Search
intervexion
Sep 19, 20212 min read
InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in METH Overdose
LITTLE ROCK, AR, USA, September 20, 2021 – InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the...
intervexion
Apr 18, 20212 min read
InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Patients with METH Use Disorder
IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary...
bottom of page